On Tuesday, Cytokinetics Inc (NASDAQ: CYTK) was 1.74% up from the session before settling in for the closing price of $50.63. A 52-week range for CYTK has been $32.50 – $110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.30%. When this article was written, the company’s average yearly earnings per share was at 3.19%. With a float of $113.59 million, this company’s outstanding shares have now reached $117.89 million.
Let’s determine the extent of company efficiency that accounts for 423 employees. In terms of profitability, gross margin is -2872.48%, operating margin of -16297.79%, and the pretax margin is -17906.24%.
Cytokinetics Inc (CYTK) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytokinetics Inc stocks. The insider ownership of Cytokinetics Inc is 3.74%, while institutional ownership is 113.34%. The most recent insider transaction that took place on Dec 02 ’24, was worth 253,800. In this transaction President & CEO of this company sold 5,000 shares at a rate of $50.76, taking the stock ownership to the 397,678 shares. Before that another transaction happened on Dec 02 ’24, when Company’s Officer proposed sale 5,000 for $50.76, making the entire transaction worth $253,786.
Cytokinetics Inc (CYTK) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.38 earnings per share (EPS) during the time that was less than consensus figure (set at -0.95) by -0.43. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
You can see what Cytokinetics Inc (CYTK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1887.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.39, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -5.37 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Looking closely at Cytokinetics Inc (NASDAQ: CYTK), its last 5-days average volume was 1.0 million, which is a drop from its year-to-date volume of 2.03 million. As of the previous 9 days, the stock’s Stochastic %D was 72.25%. Additionally, its Average True Range was 2.06.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 29.35%, which indicates a significant decrease from 39.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.57% in the past 14 days, which was higher than the 38.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $53.16, while its 200-day Moving Average is $58.60. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $52.22. Second resistance stands at $52.94. The third major resistance level sits at $54.07. If the price goes on to break the first support level at $50.37, it is likely to go to the next support level at $49.24. Should the price break the second support level, the third support level stands at $48.52.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are 118,014K outstanding shares of the company, which has a market capitalization of 6.08 billion. As of now, sales total 7,530 K while income totals -526,240 K. Its latest quarter income was 460 K while its last quarter net income were -160,550 K.